UC Davis Cancer Center researchers have discovered a metabolic deficiency in pancreatic cancer cells that can be used to slow the progress of the deadliest of all cancers.

Tumour suppressor genes do not necessarily require both alleles to be knocked out before disease phenotypes are expressed. Research published in BioMed Central's new open access journal PathoGenetics reveals that only one allele of SMAD4 has to be damaged to put a person at risk of pancreatic and colorectal cancer.

Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).

At the University of Michigan, a multidisciplinary team of researchers is investigating whether tissue optical spectroscopy can be employed for early cancer detection in the pancreas during minimally-invasive endoscopic diagnostic procedures.

In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer.

A new study has shown that evidence of past hepatitis B infection was twice as common in people with pancreatic cancer than in healthy controls. This study is the first to report an association between past exposure to the hepatitis B virus and pancreatic cancer, but researchers cautioned that more studies are necessary to evaluate the nature of the link.

A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene.

In review study, researchers say CyberKnife is a safe treatment option for recurrent pancreatic cancer in some patients and can be delivered in only a week's time

Pancreatic cancer is the fifth most common cause of cancer death in Japan. The prognosis is extremely poor because it is difficult to detect this disease in the early stage and also the postoperative incidence of recurrence is still high, and we have not had any effective treatment for inoperable patients.

A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, researchers report at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

The complete genetic blueprint for lethal pancreatic cancer and brain cancer was deciphered by a team at the Johns Hopkins Kimmel Cancer Center.

Researchers at the Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have published findings that implicate a new chemoprevention gene therapy (CGT) for preventing and treating pancreatic cancer, one of the most lethal and treatment-resistant forms of cancer.